TY - JOUR
T1 - Secondary Hyperparathyroidism and Cognitive Decline
AU - Crepeau, Philip
AU - Fedorova, Tatiana
AU - Morris-Wiseman, Lilah F.
AU - Mathur, Aarti
N1 - Publisher Copyright:
© 2023, Springer Nature Switzerland AG.
PY - 2023/6
Y1 - 2023/6
N2 - Purpose of Review: Secondary hyperparathyroidism (SHPT) likely contributes to the high prevalence of cognitive decline found among individuals with end-stage kidney disease (ESKD). Our objective is to critically evaluate the recent literature regarding the association between SHPT and cognitive decline and identify potential mechanisms. Recent Findings: Nine studies assessing the relationship between SHPT and cognition have been published in the last two decades, each showing that elevated parathyroid hormone (PTH) levels were associated with cognitive decline. One also found structural changes within the brain related to SHPT. Additionally, two found that SHPT treatment decreases the risk of cognitive decline in ESKD patients. Summary: SHPT is associated with cognitive impairment. However, the severity of SHPT associated with these changes and the specific cognitive domains affected remain unclear. Future studies are needed to focus on specific cognitive domains, the trajectory of cognitive decline, and optimal treatment strategies including the impact of kidney transplant and tertiary hyperparathyroidism.
AB - Purpose of Review: Secondary hyperparathyroidism (SHPT) likely contributes to the high prevalence of cognitive decline found among individuals with end-stage kidney disease (ESKD). Our objective is to critically evaluate the recent literature regarding the association between SHPT and cognitive decline and identify potential mechanisms. Recent Findings: Nine studies assessing the relationship between SHPT and cognition have been published in the last two decades, each showing that elevated parathyroid hormone (PTH) levels were associated with cognitive decline. One also found structural changes within the brain related to SHPT. Additionally, two found that SHPT treatment decreases the risk of cognitive decline in ESKD patients. Summary: SHPT is associated with cognitive impairment. However, the severity of SHPT associated with these changes and the specific cognitive domains affected remain unclear. Future studies are needed to focus on specific cognitive domains, the trajectory of cognitive decline, and optimal treatment strategies including the impact of kidney transplant and tertiary hyperparathyroidism.
KW - Chronic kidney disease
KW - Cognitive decline
KW - Dementia
KW - End-stage kidney disease
KW - Parathyroid hormone
KW - Secondary hyperparathyroidism
UR - http://www.scopus.com/inward/record.url?scp=85149957897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149957897&partnerID=8YFLogxK
U2 - 10.1007/s40472-023-00394-5
DO - 10.1007/s40472-023-00394-5
M3 - Review article
C2 - 38707996
AN - SCOPUS:85149957897
SN - 2196-3029
VL - 10
SP - 60
EP - 68
JO - Current Transplantation Reports
JF - Current Transplantation Reports
IS - 2
ER -